Neuregulin-1 (Nrg1) is one of the most active members of the epidermal growth factor (EGF)-like family (
1). At leastsix isoforms of Nrg1, including type I to III Nrg1α and Nrg1β, due to the alternative splicing of Nrg1 gene, have been identified (
2). Interaction of Nrg1 with the dimers of its receptors, including ErbB2, ErbB3 and ErbB4, results in many biological processes (
3-
6). Nrg1 receptors were reported to be expressed in hypothalamic astrocytes, where their activation as a result of paracrine Nrg1 stimulation, is essential for stimulating secretion of luteinising hormone-releasing hormone, as well as for puberty (
7,
8). Recently, Nrg1 was also detected in gonadotroph cells of the anterior pituitary, where it is assumed to mediate prolactin secretion from the lactotrophs in a juxtacrine manner (
4,
6). In addition, the interaction of Nrg1 with ErbB3 receptor has been reported to induce prolactin (PRL) secretion from the rat somatolactotroph GH3 cells (
5,
9). An extensive distribution of Nrg1 in the anterior pituitary was observed at Estrous 1 (E1) and E2 phases accompanied by apparent phosphorylated activation of ErbB4 in rats (
6).
In the juvenile and adult rhesus monkeys widespread expression of ErbB2, ErbB3 and ErbB4 receptor mRNAs throughout the telencephalon were reported (
10). In addition, Nrg1 was therapeutically applied in experimental heart failure in the rhesus monkey, and led to a positive therapeutic effect by impairing rapid pacing-induced apoptosis and increasing activity of PKB and Bcl-xl proteins (
11-
13). In contrast, no morphological expression of Nrg1 and its receptors was systematically described in main endocrine organs of the rhesus monkey.